Septerna (SEPN) Non-Current Deffered Revenue (2025 - 2026)
Septerna's quarterly Non-Current Deffered Revenue came in at $92.2 million in Q1 2026, down 12.97% quarter-over-quarter from $105.9 million in Q4 2025.
Septerna has reported Non-Current Deffered Revenue for 2 years, with the latest figure at $92.2 million in Q1 2026.
- For the quarter ending Q1 2026, Non-Current Deffered Revenue changed N/A year-over-year to $92.2 million; the trailing twelve-month figure through Mar 2026 stood at $92.2 million (changed N/A YoY), and the FY2025 full-year result was $105.9 million, changed N/A from the prior year.
- Non-Current Deffered Revenue for Q1 2026 stood at $92.2 million, down from $105.9 million in the prior quarter.
- The five-year high for Non-Current Deffered Revenue was $120.6 million in Q3 2025, with the low at $92.2 million in Q1 2026.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 225.10 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Septerna | 1.34 Bn | 1.34 Bn | - | 92.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 92.18 Mn |
| Dec 31, 2025 | 105.92 Mn |
| Sep 30, 2025 | 120.65 Mn |